Companies › Impact Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IMP4297 PARP inhibitor | PARP1, PARP2 | Phase 3 | Ovarian Cancer | – |
| IMP9064 DNA-PKcs inhibitor | – | Phase 1 | Solid Tumor | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04169997 | IMP4297 | Phase 3 | Ovarian Cancer | Oncology | Mar 2023 |
| NCT05269316 | IMP9064 | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
AstraZeneca Merck & Co. (MSD) Pfizer Johnson & Johnson (Janssen) GSK Eikon Therapeutics BeiGene pharmaand Allarity Therapeutics Boryung Pharmaceutical
VIVUS Allarity Therapeutics Clarity Pharmaceuticals TYK Medicines TransThera Sciences (Nanjing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.